15 recruiting. 15 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Recruiting 15 |
| Phase 2 | 7 | Recruiting 7 |
Follow Colitis, Ulcerative: new trials by email Literature Review of Colitis, Ulcerative trials Research Report on Colitis, Ulcerative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis Aletekitug (GSK1070806) - Colitis, Ulcerative | Phase 1 | Recruiting | GlaxoSmithKline | 8 | 2026-09-03 | 2026-10-28 |
| A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis Aletekitug - Colitis, Ulcerative | Phase 1 | Recruiting | GlaxoSmithKline | 16 | 2026-09-03 | 2026-11-05 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis ONO-6414, Placebo - Ulcerative Colitis (UC) | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 90 | 2026-08-20 | 2026-09-09 |
| Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study) MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole - Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | Phase 1 / Phase 2 | Recruiting | Metagen Therapeutics, Inc. | 54 | 2026-07-09 | 2026-11-03 |
| A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis INT-210 Capsule - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Innatus Therapeutics (Shanghai) Co., Ltd. | 24 | 2026-06-11 | 2026-07-09 |
| A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult BDHK-2009 Tablets, Placebo - Ulcerative Colitis (UC), Ulcerative Colitis (Disorder) | Phase 1 | Recruiting | Benethera (Shaoxing) Biotechnology Co., Ltd. | 68 | 2026-05-18 | 2026-06-08 |
| A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis MB-001, Matching placebo to MB-001 - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Mage Biologics | 100 | 2026-04-01 | 2026-10-20 |
| Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population Lyophilized Fecal Microbiota Transplantation (LFMT), Placebo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 1 | Recruiting | University of Alberta | 85 | 2026-03-01 | 2026-06-04 |
| Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg - Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 18 | 2024-11-08 | 2025-03-05 |
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis XmAb942, Placebo - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Xencor, Inc. | 270 | 2024-10-10 | 2026-10-30 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects BCD-261, dose 1, BCD-261, dose 2, BCD-261, dose 3 - Healthy | Phase 1 | Recruiting | Biocad | 48 | 2024-03-29 | 2024-12-16 |
| FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach single FMT, sequential FMT - Clostridium Difficile, Ulcerative Colitis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 64 | 2023-09-23 | 2026-03-19 |
| R-3750 in Patients With Mild to Moderate Ulcerative Colitis R-3750 - Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | Phase 1 | Recruiting | Rise Therapeutics LLC | 36 | 2023-02-27 | 2026-06-12 |
| Superdonor FMT in Patients With Ulcerative Colitis FMT, Placebo FMT - Active Ulcerative Colitis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 42 | 2023-02-13 | 2026-03-19 |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO Biospecimen Collection, Cabozantinib, Fluoropyrimidine - Autoimmune Disease, Crohn Disease | Phase 1 | Recruiting | National Cancer Institute (NCI) | 300 | 2019-07-16 | 2026-10-05 |
Inflammatory Bowel Diseases (8) · Crohn Disease (4) · Gastrointestinal Diseases (2) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Clostridium Infections (1) · Colitis (1) · Dermatomyositis (1) · Hematologic Neoplasms (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Psoriasis (1) · Scleroderma, Systemic (1)
Colonic Diseases (15) · Digestive System Diseases (15) · Gastroenteritis (15) · Intestinal Diseases (15) · Colitis (14) · Gastrointestinal Diseases (13) · Inflammatory Bowel Diseases (7) · Arthritis (1) · Autoimmune Diseases of the Nervous System (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Bone Diseases (1) · Connective Tissue Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1)
GSK1070806 (2) · CTLA-4 Antigen (1) · Fecal Microbiota Transplantation (1) · Ipilimumab (1) · Metronidazole (1) · Nivolumab (1) · Platinum Compounds (1) · Specimen Handling (1) · Vancomycin (1) · cabozantinib (1)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · GlaxoSmithKline (2) · Benethera (Shaoxing) Biotechnology Co., Ltd. (1) · Biocad (1) · Innatus Therapeutics (Shanghai) Co., Ltd. (1) · Mage Biologics (1) · Metagen Therapeutics, Inc. (1) · National Cancer Institute (NCI) (1) · Ono Pharmaceutical Co., Ltd. (1) · Rise Therapeutics LLC (1) · University Medical Center Groningen (1) · University of Alberta (1) · Xencor, Inc. (1)
United States (5) · Canada (3) · China (2) · Georgia (2) · Italy (2) · Moldova (2) · Poland (2) · Ukraine (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Croatia (1)
Arina V Zinkina-Orikhan, PhD (1) · Gianluca Ianiro (1) · Gianluca Ianiro, MD (1) · Hussein A Tawbi (1) · Jinliang Chen (1) · Minhu Chen (1) · Project Leader (1)
2025 (1), UM1CA186688 (1)